MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

In our case, the sole barrier identified by the FDA was the new clinical exclusivity granted to TYVASO DPI, which expires on May 23, 2025. As directed in the tentative approval label, we plan to ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in the ...